Search

Your search keyword '"Mi, Joanna"' showing total 7 results
Start Over Author "Mi, Joanna" Publication Year Range Last 50 years
7 results on '"Mi, Joanna"'

1. Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

Author

Kumar, Anita, Soumerai, Jacob, Abramson, Jeremy S., Barnes, Jeffrey A., Caron, Philip, Chhabra, Shalini, Chabowska, Maria, Dogan, Ahmet, Falchi, Lorenzo, Grieve, Clare, Haydu, J. Erika, Johnson, Patrick Connor, Joseph, Ashlee, Kelly, Hailey E., Labarre, Alyssa, Lue, Jennifer Kimberly, Martignetti, Rosalba, Mi, Joanna, Moskowitz, Alison, Owens, Colette, Plummer, Sean, Puccio, Madeline, Salles, Gilles, Seshan, Venkatraman, Simkins, Elizabeth, Slupe, Natalie, Zhang, Honglei, and Zelenetz, Andrew D.

Published
2025
Full Text
View/download PDF

2. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial

Author

Soumerai, Jacob D, Mato, Anthony R, Dogan, Ahmet, Seshan, Venkatraman E, Joffe, Erel, Flaherty, Kelsey, Carter, Jason, Hochberg, Ephraim, Barnes, Jeffrey A, Hamilton, Audrey M, Abramson, Jeremy S, Batlevi, Connie L, Matasar, Matthew J, Noy, Ariela, Owens, Colette N, Palomba, M Lia, Kumar, Anita, Takvorian, Tak, Ni, Ai, Choma, Morgan, Friedman, Chaya, Chadha, Puja, Simkins, Elizabeth, Ruiters, Jade, Sechio, Sidney, Portman, Daneal, Ramos, Lauren, Nolet, Natascha, Mahajan, Neena, Martignetti, Rosalba, Mi, Joanna, Scorsune, Krista, Lynch, Julia, McGree, Brianne, Hughes, Stephanie, Grieve, Clare, Roeker, Lindsey E, Thompson, Meghan, Johnson, P Connor, Roshal, Mikhail, Huang, Jane, Biondo, Juliana, Wu, Qun, Jacob, Allison, Abdel-Wahab, Omar, and Zelenetz, Andrew D

Published
2021
Full Text
View/download PDF

3. Preliminary Safety and Efficacy from a Multicenter, Investigator-Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen)

Author

Kumar, Anita, primary, Soumerai, Jacob D., additional, Abramson, Jeremy S., additional, Batlevi, Connie Lee, additional, Chadha, Puja, additional, Dogan, Ahmet, additional, Falchi, Lorenzo, additional, Flaherty, Kelsey, additional, Friedman, Chaya, additional, Grieve, Clare, additional, Ho, Caleb, additional, Johnson, P. Connor, additional, Joseph, Ashlee, additional, Khan, Niloufer, additional, Mi, Joanna, additional, Martignetti, Rosalba, additional, Matasar, Matthew J., additional, Owens, Colette, additional, Ruiters, Jade, additional, Sechio, Sidney, additional, Seshan, Venkatraman, additional, Simkins, Elizabeth, additional, Abdel-Wahab, Omar, additional, and Zelenetz, Andrew D., additional

Published
2021
Full Text
View/download PDF

4. Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence

Author

Soumerai, Jacob D., primary, Mato, Anthony R., additional, Dogan, Ahmet, additional, Seshan, Venkatraman, additional, Joffe, Erel, additional, Flaherty, Kelsey, additional, Carter, Jason, additional, Hochberg, Ephraim P, additional, Barnes, Jeffrey A, additional, Hamilton, Audrey, additional, Abramson, Jeremy S., additional, Batlevi, Connie Lee, additional, Matasar, Matthew J., additional, Noy, Ariela, additional, Owens, Colette, additional, Palomba, M. Lia, additional, Kumar, Anita, additional, Takvorian, Tak, additional, Ni, Ai, additional, Choma, Morgan, additional, Friedman, Chaya, additional, Chadha, Puja, additional, Simkins, Elizabeth, additional, Ruiters, Jade, additional, Sechio, Sidney, additional, Portman, Daneal, additional, Nolet, Natascha, additional, Mahajan, Neena, additional, Martignetti, Rosalba, additional, Mi, Joanna, additional, Scorsune, Krista J, additional, Lynch, Julia M, additional, McGree, Brianne, additional, Hughes, Stephanie Y, additional, Grieve, Clare, additional, Roeker, Lindsey E., additional, Thompson, Meghan C., additional, Johnson, P. Connor, additional, Roshal, Mikhail, additional, Huang, Jane, additional, Biondo, Juliana M.L., additional, Wu, Jenny Qun, additional, Jacob, Allison P., additional, Abdel-Wahab, Omar, additional, and Zelenetz, Andrew D., additional

Published
2021
Full Text
View/download PDF

5. A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma

Author

Kumar, Anita, Soumerai, Jacob, Abramson, Jeremy S., Barnes, Jeffrey A., Caron, Philip, Chabowska, Maria, Devlin, Mary, Dogan, Ahmet, Falchi, Lorenzo, Garcia, Rayna N., Grieve, Clare, Haskell, Emma, Haydu, Julie E., Johnson, Patrick Connor, Joseph, Ashlee, Kelly, Hailey E., Labarre, Alyssa, Littlejohn, Emerald D, Lue, Jennifer Kimberly, Mi, Joanna, Martignetti, Rosalba, McCambridge, Grace, Moskowitz, Alison, Owens, Colette, Plummer, Sean F., Puccio, Madeline G., Salles, Gilles, Seshan, Venkatraman, Slupe, Natalie, and Zelenetz, Andrew D.

Published
2023
Full Text
View/download PDF

6. Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53mutation

Author

Kumar, Anita, Soumerai, Jacob, Abramson, Jeremy S., Barnes, Jeffrey A., Caron, Philip, Chhabra, Shalini, Chabowska, Maria, Dogan, Ahmet, Falchi, Lorenzo, Grieve, Clare, Haydu, Julie E., Johnson, Patrick Connor, Joseph, Ashlee, Kelly, Hailey E., Labarre, Alyssa, Lue, Jennifer Kimberly, Martignetti, Rosalba, Mi, Joanna, Moskowitz, Alison, Owens, Colette, Plummer, Sean, Puccio, Madeline, Salles, Gilles, Seshan, Venkatraman, Simkins, Elizabeth, Slupe, Natalie, Zhang, Honglei, and Zelenetz, Andrew D.

Abstract

•BOVen was safe and effective for the frontline treatment of TP53-mutant MCL.•The 2-year progression-free survival of 72% compares favorably with previously reported outcomes with chemoimmunotherapy in TP53-mutant MCL.

Published
2024
Full Text
View/download PDF

7. A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer.

Author

Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin AM, Fong L, and Ryan CJ

Subjects
Adenocarcinoma blood, Aged, Aged, 80 and over, Antineoplastic Agents pharmacokinetics, Humans, Male, Masoprocol pharmacokinetics, Middle Aged, Prostate-Specific Antigen blood, Prostatic Neoplasms blood, Receptors, Somatomedin antagonists & inhibitors, Adenocarcinoma drug therapy, Antineoplastic Agents therapeutic use, Masoprocol therapeutic use, Prostatic Neoplasms drug therapy
Abstract

Insulin-like growth factor (IGF)-mediated signaling is a newly recognized clinical target in prostate cancer, and it is hypothesized that blockade of the IGF receptor (IGF1R) will impair downstream signaling and slow tumor growth. In this study the efficacy of nordihydroguaiaretic acid (NDGA), a small molecule inhibitor of the IGF-1R, was prospectively evaluated in patients with non-metastatic hormone-sensitive prostate cancer (HSPC). Eligible patients had non-metastatic HSPC with a rising prostate-specific antigen (PSA) and a normal testosterone level. NDGA 2000 mg was given orally daily in 28 day cycles and treatment continued until PSA progression or toxicity. Accrual was stopped early after a pre-planned interim analysis showed no significant PSA declines after 3 cycles of treatment among the first 12 patients enrolled. Median time on treatment was 9 cycles (range 2-19) for 11 patients now off study; 1 patient continues to receive therapy and has been on study for 29 months. Seven patients experienced non-sustained declines in PSA ranging from 1.9 to 15.8% of baseline. PSADT lengthened by a median of 1.4 months for all evaluable patients when compared to pretreatment PSADT (range -6.1 to +19.8 months). Grade 3 events were rare and included nausea/vomiting, syncope due to dehydration, and elevated liver function tests in 1 patient, and cognitive disturbance in another patient. NDGA therapy lengthens median PSADT but does not induce significant PSA declines. Further study may require a placebo-control to determine if changes in PSADT are drug related.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results